ASPI

ASPI is a speculative, pre-commercialization advanced-materials story being priced as if execution is already de-risked. The 10-K is explicit that the company has 'no sales attributable to enriched isotopes' and is 'targeting initial commercial shipments' of C-14, Si-28 and Yb-176 only in mid-2026 or Q3 2026 — meaning the reported FY2025 revenue of $23.8M is not from the core isotope thesis at all, and the YoY +475% growth is flattered by the January 2026 Renergen acquisition and the August 2025 Skyline (Hong Kong civil engineering) consolidation rather than enrichment volumes. At a $812M market cap and 34.1x sales, the price embeds confident commercial-scale isotope output that has not yet occurred.

The fundamentals underneath the narrative are deeply unprofitable and getting worse, not better. Net income collapsed to -$160M (YoY -393%) on just $23.8M of revenue — a -670% net margin — operating margin is -251%, ROE is -78%, and operating cash flow is -$37.8M. Gross margin is only 14.3% on the small revenue base that does exist, which is not indicative of a high-margin specialty-materials business at this stage. Share count is up 74.7% YoY to 126M, confirming that the $286M cash pile was bought through heavy dilution, and management openly warns it 'will require substantial additional capital… which may not be available on acceptable terms, or at all.' Accumulated deficit is -$231M.